File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/0014-2999(91)90362-T
- Scopus: eid_2-s2.0-0025854892
- PMID: 1654260
- WOS: WOS:A1991FN11000006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The calcium channel antagonist S 11568 causes endothelium-dependent relaxation in canine arteries
Title | The calcium channel antagonist S 11568 causes endothelium-dependent relaxation in canine arteries |
---|---|
Authors | |
Keywords | Bioassay Ca2+ channel antagonists cGMP Coronary artery (dog) EDRF (endothelium-derived relaxing factor) Femoral artery (dog) |
Issue Date | 1991 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar |
Citation | European Journal Of Pharmacology, 1991, v. 197 n. 1, p. 41-48 How to Cite? |
Abstract | The new dihydropyridine calcium channel antagonist S 11568 and its optical isomers, S 12967 and S 12968 (3 x 10-6 to 10-4 M), caused, unlike nifedipine (10-4 M), equipotent and rapid endothelium-dependent relaxations and increased the content of cyclic GMP in rings of canine femoral arteries. These effects were observed in the presence of indomethacin and were prevented by methylene blue, hemoglobin and N(G)-monomethyl-L-arginine. Thus these effects must involve endothelium-derived relaxing factor (EDRF) and be distinct from the calcium channel antagonistic effect, which is stereoselective and of slow onset. The compounds did not potentiate relaxations of rings without endothelium to nitric oxide. In bioassay experiments, the compounds produced endothelium-dependent relaxation only when applied to endothelial donors. These results are compatible with an increased release of EDRF induced by the dihydropyridine compounds. |
Persistent Identifier | http://hdl.handle.net/10722/171010 |
ISSN | 2023 Impact Factor: 4.2 2023 SCImago Journal Rankings: 1.055 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vilaine, JP | en_US |
dc.contributor.author | Biondi, ML | en_US |
dc.contributor.author | Villeneuve, N | en_US |
dc.contributor.author | Feletou, M | en_US |
dc.contributor.author | Peglion, JL | en_US |
dc.contributor.author | Vanhoutte, PM | en_US |
dc.date.accessioned | 2012-10-30T06:11:49Z | - |
dc.date.available | 2012-10-30T06:11:49Z | - |
dc.date.issued | 1991 | en_US |
dc.identifier.citation | European Journal Of Pharmacology, 1991, v. 197 n. 1, p. 41-48 | en_US |
dc.identifier.issn | 0014-2999 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/171010 | - |
dc.description.abstract | The new dihydropyridine calcium channel antagonist S 11568 and its optical isomers, S 12967 and S 12968 (3 x 10-6 to 10-4 M), caused, unlike nifedipine (10-4 M), equipotent and rapid endothelium-dependent relaxations and increased the content of cyclic GMP in rings of canine femoral arteries. These effects were observed in the presence of indomethacin and were prevented by methylene blue, hemoglobin and N(G)-monomethyl-L-arginine. Thus these effects must involve endothelium-derived relaxing factor (EDRF) and be distinct from the calcium channel antagonistic effect, which is stereoselective and of slow onset. The compounds did not potentiate relaxations of rings without endothelium to nitric oxide. In bioassay experiments, the compounds produced endothelium-dependent relaxation only when applied to endothelial donors. These results are compatible with an increased release of EDRF induced by the dihydropyridine compounds. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/ejphar | en_US |
dc.relation.ispartof | European Journal of Pharmacology | en_US |
dc.subject | Bioassay | - |
dc.subject | Ca2+ channel antagonists | - |
dc.subject | cGMP | - |
dc.subject | Coronary artery (dog) | - |
dc.subject | EDRF (endothelium-derived relaxing factor) | - |
dc.subject | Femoral artery (dog) | - |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Arginine - Analogs & Derivatives - Pharmacology | en_US |
dc.subject.mesh | Calcium Channel Blockers - Pharmacology | en_US |
dc.subject.mesh | Cyclic Gmp - Metabolism | en_US |
dc.subject.mesh | Dihydropyridines - Pharmacology | en_US |
dc.subject.mesh | Dogs | en_US |
dc.subject.mesh | Endothelium, Vascular - Metabolism - Physiology | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Hemoglobins - Metabolism | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Methylene Blue - Pharmacology | en_US |
dc.subject.mesh | Muscle Relaxation - Drug Effects | en_US |
dc.subject.mesh | Muscle, Smooth, Vascular - Drug Effects - Metabolism | en_US |
dc.subject.mesh | Nitric Oxide - Pharmacology | en_US |
dc.subject.mesh | Omega-N-Methylarginine | en_US |
dc.title | The calcium channel antagonist S 11568 causes endothelium-dependent relaxation in canine arteries | en_US |
dc.type | Article | en_US |
dc.identifier.email | Vanhoutte, PM:vanhoutt@hku.hk | en_US |
dc.identifier.authority | Vanhoutte, PM=rp00238 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/0014-2999(91)90362-T | - |
dc.identifier.pmid | 1654260 | - |
dc.identifier.scopus | eid_2-s2.0-0025854892 | en_US |
dc.identifier.volume | 197 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.spage | 41 | en_US |
dc.identifier.epage | 48 | en_US |
dc.identifier.isi | WOS:A1991FN11000006 | - |
dc.publisher.place | Netherlands | en_US |
dc.identifier.scopusauthorid | Vilaine, JP=7004617134 | en_US |
dc.identifier.scopusauthorid | Biondi, ML=7005127265 | en_US |
dc.identifier.scopusauthorid | Villeneuve, N=7003458215 | en_US |
dc.identifier.scopusauthorid | Feletou, M=7006461826 | en_US |
dc.identifier.scopusauthorid | Peglion, JL=7003361098 | en_US |
dc.identifier.scopusauthorid | Vanhoutte, PM=7202304247 | en_US |
dc.identifier.issnl | 0014-2999 | - |